Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Total Debt (2016 - 2025)

Amphastar Pharmaceuticals has reported Total Debt over the past 13 years, most recently at $610.4 million for Q4 2025.

  • Quarterly results put Total Debt at $610.4 million for Q4 2025, up 1.42% from a year ago — trailing twelve months through Dec 2025 was $610.4 million (up 1.42% YoY), and the annual figure for FY2025 was $610.4 million, up 1.42%.
  • Total Debt for Q4 2025 was $610.4 million at Amphastar Pharmaceuticals, roughly flat from $609.5 million in the prior quarter.
  • Over the last five years, Total Debt for AMPH hit a ceiling of $638.6 million in Q3 2023 and a floor of $38.5 million in Q2 2021.
  • Median Total Debt over the past 5 years was $544.2 million (2023), compared with a mean of $358.0 million.
  • Biggest five-year swings in Total Debt: dropped 7.02% in 2021 and later surged 743.74% in 2023.
  • Amphastar Pharmaceuticals' Total Debt stood at $77.0 million in 2021, then dropped by 1.42% to $75.9 million in 2022, then surged by 677.51% to $590.0 million in 2023, then grew by 2.01% to $601.9 million in 2024, then rose by 1.42% to $610.4 million in 2025.
  • The last three reported values for Total Debt were $610.4 million (Q4 2025), $609.5 million (Q3 2025), and $608.7 million (Q2 2025) per Business Quant data.